Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • SNPsaurus
    Registered Vendor
    • May 2013
    • 525

    SNPsaurus launches nextRAD services

    SNPsaurus announces launch of nextRAD genotyping
    Enables genotyping by sequencing on low input samples

    May 15, 2013. SNPsaurus, a genomic services company based in Eugene, Oregon, today announced the launch of their nextRAD genotyping platform. The nextRAD (Nextera-tagmented reductively-amplified DNA) marker platform is designed for genotyping large populations and for samples with limited availability of genomic DNA.

    “The distinguishing feature of nextRAD compared to other genotyping-by-sequencing methods is that it does not use restriction enzymes to reduce the complexity of the genome.” said SNPsaurus founder Eric Johnson. “This allows us to make high quality sequencing libraries that sample thousands to hundreds of thousands of loci across a genome from less than 10 ng total genomic DNA.”

    Director of Research Paul Etter said, “We tried to design nextRAD for the rapidly increasing capabilities of next-generation sequencers. It has the throughput for genotyping thousands of samples because of the streamlined protocol and the ability to multiplex hundreds of samples in a lane of a sequencer.”

    SNPsaurus also unveiled their nextRAD Project Explorer, at http://snpsaurus.com/project/, an online tool for exploring the parameters of a genotyping project, from low-coverage mapping of recombinant inbred lines to high-coverage genotyping for creating genetic maps, and getting a project price estimate.

    SNPsaurus has licensed nextRAD technology from the University of Oregon.

    About SNPsaurus
    SNPsaurus is a privately owned genomic services company founded in 2013. Based in Eugene, Oregon, SNPsaurus works with researchers to rapidly provide high-quality genotyping data.

    contact:
    Eric Johnson, founder
    [email protected]
    Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com
  • SNPsaurus
    Registered Vendor
    • May 2013
    • 525

    #2
    I've added a blog post about how researchers are finding uses for low-depth sequencing, with a nice paper from Beth Shapiro's group about polar bears as an example.

    How low can you go?
    Providing nextRAD genotyping and PacBio sequencing services. http://snpsaurus.com

    Comment

    Latest Articles

    Collapse

    • mylaser
      Reply to Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by mylaser
      Kheloyaar: The Complete Guide to Kheloyaar Loginand Kheloyaar ID
      The online gaming industry has transformed the way people enjoy digital entertainment. As technology continues to improve, players are looking for platforms that offer convenience, security, and a seamless user experience. Kheloyaarhas gained attention among users who value an easy-to-use platform, quick account access, and a simple registration process.
      Whether you're exploring Kheloyaar for the first time or want to understand...
      Today, 09:27 PM
    • SEQadmin2
      Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
      by SEQadmin2



      Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
      ...
      Today, 11:10 AM
    • SEQadmin2
      Cancer Drug Resistance: The Lingering Barrier to Rising Survival
      by SEQadmin2



      Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

      There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
      Yesterday, 05:17 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Topics Statistics Last Post
    Started by SEQadmin2, Today, 10:04 AM
    0 responses
    8 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, Yesterday, 10:08 AM
    0 responses
    7 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-07-2026, 11:05 AM
    0 responses
    9 views
    0 reactions
    Last Post SEQadmin2  
    Started by SEQadmin2, 07-02-2026, 11:08 AM
    0 responses
    31 views
    0 reactions
    Last Post SEQadmin2  
    Working...